GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Rennova Health Inc (OTCPK:RNVA) » Definitions » EV-to-EBITDA

Rennova Health (Rennova Health) EV-to-EBITDA : 3.03 (As of May. 06, 2024)


View and export this data going back to 1995. Start your Free Trial

What is Rennova Health EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Rennova Health's enterprise value is $16.17 Mil. Rennova Health's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 was $5.34 Mil. Therefore, Rennova Health's EV-to-EBITDA for today is 3.03.

The historical rank and industry rank for Rennova Health's EV-to-EBITDA or its related term are showing as below:

RNVA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -775.03   Med: -3.21   Max: 54.2
Current: 3.03

During the past 13 years, the highest EV-to-EBITDA of Rennova Health was 54.20. The lowest was -775.03. And the median was -3.21.

RNVA's EV-to-EBITDA is ranked better than
87.07% of 116 companies
in the Medical Diagnostics & Research industry
Industry Median: 16.3 vs RNVA: 3.03

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-06), Rennova Health's stock price is $0.0001. Rennova Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $0.000. Therefore, Rennova Health's PE Ratio for today is N/A.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Rennova Health EV-to-EBITDA Historical Data

The historical data trend for Rennova Health's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rennova Health EV-to-EBITDA Chart

Rennova Health Annual Data
Trend Mar13 Mar14 Mar15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -18.19 -14.44 -69.31

Rennova Health Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.55 -69.31 6.04 2.96 2.96

Competitive Comparison of Rennova Health's EV-to-EBITDA

For the Diagnostics & Research subindustry, Rennova Health's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rennova Health's EV-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Rennova Health's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Rennova Health's EV-to-EBITDA falls into.



Rennova Health EV-to-EBITDA Calculation

Rennova Health's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=16.170/5.336
=3.03

Rennova Health's current Enterprise Value is $16.17 Mil.
Rennova Health's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.34 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Rennova Health  (OTCPK:RNVA) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Rennova Health's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.0001/0.000
=N/A

Rennova Health's share price for today is $0.0001.
Rennova Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Rennova Health EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Rennova Health's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Rennova Health (Rennova Health) Business Description

Traded in Other Exchanges
N/A
Address
400 S. Australian Avenue, Suite 800, West Palm Beach, FL, USA, 33401
Rennova Health Inc is a vertically integrated provider of healthcare-related products and services. The company operates through a single business segment namely the Hospital operations segment reflects the purchase of the hospital assets. Geographically, the activities are carried out throughout the region of the US.
Executives
Jonathan Immordino officer: Chief Financial Officer 3340, POSEIDON WAY, INDIALANTIC FL 32903
Marlene Mclennan officer: Chief Financial Officer 400 SOUTH AUSTRALIAN AVENUE, SUITE 800, WEST PALM BEACH FL 33401
Gary L Blum director 3278 WILSHIRE BOULEVARD, SUITE 603, LOS ANGELES, CALIFORNIA CA 90010
John Beach director 400 S. AUSTRALIAN AVENUE,, SUITE 800,, WEST PALM BEACH, FL 33401
Kamran Ajami director 3920 NW 43RD ST., COCONUT CREEK FL 33073
Trevor Langley director 1000 N. GREEN VALLEY PARKWAY, #440-420, HENDERSON NV 89074
Michael H Pollack officer: Interim CFO 114 WEST 47TH STREET, 19TH FLOOR, NEW YORK NY 10036
Sharon Lynne Hollis 10 percent owner 400 SOUTH AUSTRALIAN AVENUE, 8TH FLOOR, WEST PALM BEACH FL 33401
Robert P Lee director 400 S. AUSTRALIAN AVE., #800, WEST PALM BEACH FL 33134
Aella, Ltd. 10 percent owner SUITE 104A, SAFFREY SQUARE, BANK LANE, PO BOX N-9306, NASSAU C5 000000
Epizon Ltd. 10 percent owner SUITE 104A, SAFFREY SQUARE, BANK LANE, PO BOX N-9306, NASSAU C5 000000
Michael Louis Goldberg director 2008 BAYVIEW DRIVE, FORT LAUDERDALE FL 33305
Benjamin Frank director 400 SOUTH AUSTRALIAN AVENUE, 8TH FLOOR, WEST PALM BEACH FL 33401
Jason Adams officer: Chief Financial Officer 4700 SANTA DEL RAE AVENUE, FT MYERS FL 33901
George Lundberg officer: Editor in Chief and CMO 44 MONTGOMERY STREET, SUITE 800, SAN FRANCISCO CA 94104